Of note, six cell lines with KRAS mutation [two t(17;19)‐ALL cell lines and four t(1;19)‐ALL cell lines] were relatively more sensitive to selumetinib than 14 cell lines without KRAS mutation [two t(17;19)‐ALL cell lines and 12 t(1;19)‐ALL cell lines] (P = 0.060 in Mann‐Whitney test). This evidence concerns the gene KRAS and acute lymphoblastic leukemia.